

June 18, 2020

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to above, please find enclosed the disclosure of Related Party Transactions, on consolidated basis, for the year ended March 31, 2020 drawn in accordance with applicable accounting standards.

This is for your information and records.

For Strides Pharma Science Limited

Manjula Ramamurthy **Company Secretary**

Encl: A/a

Strides Pharma Science Limited

Disclosure of Related Party Transactions on a Consolidated Basis

(In pursuance with Regulation 23(9) of SEBI (Lisitng Obligations and Disclosure Requirements) Regulations, 2015)

Strides Pharma Science Limited CIN: L24230MH1990PLC057062

Name of Related parties and Description of Relationships

Relationship	Name				
Joint Ventures (JV)	MyPak Solutions Australia Pty Ltd, Australia (upto July 10, 2019)				
	Sihuan Strides (HK) Limited, Hongkong (with effect from Oct 22, 2019)				
	Oraderm Pharmaceuticals Pty Ltd, Australia (upto July 10, 2019)				
Associates	Aponia Laboratories Inc, USA				
	Eris Pharma GmbH, Germany (with effect from September 9, 2019)				
	Fairmed Healthcare AG, Switzerland (with effect from September 9, 2019)				
	Fairmed Healthcare GmbH, Germany (with effect from September 9, 2019)				
	Generic Partners (R&D) Pte. Ltd, Singapore (Up to July 15, 2019)				
	Juno OTC Inc., Canada (with effect from May 31, 2019)				
	Regional Bio Equivalence Centre S.C., Ethiopia				
	Stelis Biopharma Private Limited, India				
	Stelis Biopharma LLC, USA (with effect from Jan 21, 2020)				
	Stelis Pte. Ltd, Singapore				
	Strides Consumer Private Limited, India				
	Strides Consumer LLC, USA				
	Strides Global Consumer Healthcare Limited, UK				
Directors and Key Management	Mr. Deepak Vaidya, Chairman and Non-Executive Director				
Personnel	Mr. Arun Kumar, Managing Director & Group CEO - (Up to Jan 8, 2020), Executive Director (with effect from				
	Jan 9, 2020)				
	Dr. R Ananthanarayanan, CEO & Managing Director - (with effect from Jan 9 ,2020)				
	Mr. Badree Komandur, Executive Director- Finance & Group CFO				
	Mr. Bharat D Shah, Independent Director				
	Mr. S.Sridhar, Independent Director				
	Mrs. Sangita Reddy, Independent Director (Up to July 30, 2019)				
	Dr. Kausalya Santhanam, Independent Director (with effect from Dec 11, 2019)				
	Mr. Homi Rustam Khusrokhan, Independent Director				
	Ms. Manjula Ramamurthy, Company Secretary				
Enterprises owned or	Agnus Capital LLP, India				
significantly influenced by	Alivira Animal Health Limited, India				
directors, key management	Atma Projects, India				
personnel and their Relatives	Aurore Life Sciences Private Limited, India				
	Aurore Pharmaceuticals Private Limited, India				
	Chayadeep Properties Private Limited, India				
	Devendra Estates LLP, India				
	Sovizen Life Sciences Private Limited, India (Renamed as Steriscience Private Limited on April 15, 2020)				
	Tenshi Kaizen Private Limited, India				
	Tenshi Life Sciences Private Limited, India				
	Tenshi Life Care Private Limited, India				
	Tenshi Kaizen USA Inc, USA				
	Tenshi Ventures LLP, India				
	Naari Pharma Private Limited, India				
	Naari Pte Ltd, Singapore				
	Solara Active Pharma Sciences Limited, India				
	Shasun USA Inc, USA				
	SeQuent Scientific Limited, India				
	SeQuent Research Limited, India				
	Strides Chemicals Private Limited, India (Merged with Solara Active Pharma Sciences Limited on 1st Feb				
	2020, with an appointed date of Sep 1, 2018)				
	White Crow Research Private Limited, India				



CIN: L24230MH1990PLC057062

CONSOLIDATED RELATED PARTY TRANSACTIONS FOR THE YEAR ENDED MARCH 31,2020

(Rs Million)

RPT Classification	Company Name	Joint Venture/Associates	Directors / Key Managerial Personnel	Enterprises Owned or Significantly Influenced by Directors or KMP or their Relatives	Grand Total
	Fairmed Healthcare AG	102.79	-	-	102.79
	Juno OTC Inc.	17.46	-	-	17.46
	Mypak Solutions Australia Pty Ltd	(0.14)	-	-	(0.14)
Sale of Products/ Services (net	Sihuan Strides (HK) Limited	85.27	-	-	85.27
of returns)	Solara Active Pharma Sciences Limited	-	-	24.23	24.23
or returns)	Strides Consumer LLC	26.47	-	-	26.47
	Strides Consumer Private Limited	7.11	-	-	7.11
	Tenshi Kaizen Private Limited	-	-	0.14	0.14
	Tenshi Kaizen USA Inc.	-	ı	0.78	0.78
	Agnus Capital LLP	-	-	1.60	1.60
	Aurore Life Sciences Private Limited	-	-	0.60	0.60
	Naari Pharma Private Limited	-	-	24.13	24.13
	Shasun USA Inc	-	-	21.80	21.80
	Solara Active Pharma Sciences Limited	-	-	85.15	85.15
	Sovizen Life Sciences Private Limited	-	-	3.00	3.00
Support Service Income	Stelis Biopharma Private Limited	27.14	-	-	27.14
Support Service income	Strides Consumer LLC	7.83	-	-	7.83
	Strides Consumer Private Limited	3.68	-	-	3.68
	Strides Global Consumer Healthcare Limited	4.30	-	-	4.30
	Tenshi Kaizen Private Limited	-	-	16.66	16.66
	Tenshi Kaizen USA Inc.	-	-	6.00	6.00
	Tenshi Life Care Private Limited	-	-	1.21	1.21
	Tenshi Life Sciences Private Limited	-	-	30.19	30.19

CIN: L24230MH1990PLC057062

CONSOLIDATED RELATED PARTY TRANSACTIONS FOR THE YEAR ENDED MARCH 31,2020

(Rs Million)

RPT Classification	Company Name	Joint Venture/Associates	Directors / Key Managerial Personnel	Enterprises Owned or Significantly Influenced by Directors or KMP or their Relatives	Grand Total
Rental Income	Solara Active Pharma Sciences Limited	-	-	14.46	14.46
Rental Income	Strides Consumer Private Limited	0.76	-	-	0.76
Danasit Baild	Atma Projects	-	-	19.83	19.83
Deposit Paid	Chayadeep Properties Private Limited	-	-	15.56	15.56
Guarantee Commission Received	Stelis Biopharma Private Limited	39.77	=	-	39.77
	Fairmed Healthcare AG	0.25	=	-	0.25
	Juno OTC Inc.	0.22	-	-	0.22
Interest Income	Stelis Biopharma Private Limited	7.26	-	-	7.26
	Strides Consumer Private Limited	3.01	-	-	3.01
	Generic Partners (R&D) Pte Ltd	12.28	_	-	12.28
Sale of Property, plant and	Naari Pharma Private Limited	-	-	0.01	0.01
equipment					
- qp	Aurore Life Sciences Private Limited	-	-	0.48	0.48
	Aurore Pharmaceuticals Private Limited	-	-	0.05	0.05
	Mypak Solutions Australia Pty Ltd	67.39	-	- 244	67.39
Purchase of Products/Services	SeQuent Research Limited	-	-	3.11	3.11
Turenase of Froducts, services	Solara Active Pharma Sciences Limited	- 0.45	-	2,962.09	2,962.09
	Strides Global Consumer Healthcare Limited Tenshi Kaizen Private Limited	9.15	-	- 0.20	9.15
		-	-	0.38	0.38
	White Crow Research Private Limited	-	-	5.42	5.42
Purchase of Property, plant and	Naari Pte Ltd.	-	=	0.67	0.67
equipment					
Lease Payments	Atma Projects	-	-	68.45	68.45
	Chayadeep Properties Private Limited	-	-	29.00	29.00
	Devendra Estates LLP	-	-	3.33	3.33
Investment during the year	Fairmed Healthcare AG	171.03	-	-	171.03
	Sihuan Strides (HK) Limited	184.59	-	-	184.59
	Stelis Biopharma Private Limited	905.04	-	-	905.04

CIN: L24230MH1990PLC057062

CONSOLIDATED RELATED PARTY TRANSACTIONS FOR THE YEAR ENDED MARCH 31,2020

(Rs Million)

RPT Classification	Company Name	Joint Venture/Associates	Directors / Key Managerial Personnel	Enterprises Owned or Significantly Influenced by Directors or KMP or their Relatives	Grand Total
	Aurore Life Sciences Private Limited	-	-	15.75	15.75
Loans / Advances given/ repaid	Fairmed Healthcare AG	120.93	-	-	120.93
by the company to	Juno OTC Inc.	89.77	-	-	89.77
	Naari Pharma Private Limited	-	-	3.37	3.37
Loans / Advances taken/repaid	Stelis Biopharma Private Limited	250.00	-	-	250.00
to the company by					
	Naari Pharma Private Limited	-	-	2.94	2.94
	Solara Active Pharma Sciences Limited	-	-	16.35	16.35
	Stelis Biopharma Private Limited	15.73	-	-	15.73
Reimbursement of expenses	Stelis Pte Ltd	0.71	-	-	0.71
incurred on behalf of	Strides Consumer LLC	9.98	-	-	9.98
	Strides Consumer Private Limited	6.24	-	-	6.24
	Tenshi Kaizen Private Limited	-	-	2.94	2.94
	Tenshi Life Sciences Private Limited	-	-	5.23	5.23
	Chayadeep Properties Private Limited	-	-	2.81	2.81
	Juno OTC Inc.	1.02	-	-	1.02
Paimbursoment of evnences	Mypak Solutions Australia Pty Ltd	0.29	-	-	0.29
Reimbursement of expenses	SeQuent Scientific Limited	-	-	1.38	1.38
incurred by	Solara Active Pharma Sciences Limited	-	-	148.62	148.62
	Strides Consumer Private Limited	0.01	-	-	0.01
	Tenshi Life Care Private Limited	=	-	0.15	0.15
Share Application Money paid	Stelis Biopharma Private Limited	25.00	-	-	25.00
	Dr. R Ananthanarayanan	-	32.97	-	32.97
Short term Employment benefits	Mr. Badree Komandur	-	37.20	-	37.20
(refer note (i))	Ms. Manjula Ramamurthy	-	3.99	-	3.99
	Mr. Arun Kumar	-	72.08	-	72.08

CIN: L24230MH1990PLC057062

CONSOLIDATED RELATED PARTY TRANSACTIONS FOR THE YEAR ENDED MARCH 31,2020

(Rs Million)

RPT Classification	Company Name	Joint Venture/Associates	Directors / Key Managerial Personnel	Enterprises Owned or Significantly Influenced by Directors or KMP or their Relatives	Grand Total
Employee stock option expenses	Mr. Badree Komandur	-	1.65	-	1.65
Employee stock option expenses	Ms. Manjula Ramamurthy	-	0.33	-	0.33
	Mr. Bharat D Shah	-	1.00	-	1.00
Remuneration to Non-executive	Dr. Kausalya Santhanam	-	0.33	ı	0.33
directors	Mr. Deepak Vaidya	-	1.00	ı	1.00
	Mr. S.Sridhar	=	1.00	-	1.00
	Mr. Homi Rustam Khusrokhan	-	1.00	1	1.00
Sitting fees to Directors	Mr. Bharat D Shah	-	1.84	ı	1.84
	Dr. Kausalya Santhanam	-	0.61	ı	0.61
	Mr. Deepak Vaidya	-	1.20	1	1.20
	Mr. S.Sridhar	-	1.20	1	1.20
	Mr. Homi Rustam Khusrokhan	-	1.00	1	1.00
	Mrs. Sangita Reddy	-	0.30	-	0.30

Note (i): The compensation excludes gratuity & compensated absences which cannot be separately identified from the composite amount advised by the actuary.

